<DOC>
	<DOCNO>NCT02332928</DOCNO>
	<brief_summary>This double-blind , placebo-controlled trial wherein subject breast cancer randomize receive either 20 mg oral melatonin placebo night first RT , nightly throughout RT , additional 2 week follow completion RT . After informed consent obtain eligible subject , electronically randomize 1:1 ratio melatonin treatment placebo . The subject stratify accord treatment duration ( le 3 week ; equal great 3 week ) prior chemotherapy .</brief_summary>
	<brief_title>Melatonin Supplementation Cancer-related Fatigue Patients Receiving Radiotherapy</brief_title>
	<detailed_description>Subjects randomize receive either melatonin placebo . Subjects receive 20-mg oral melatonin placebo night first RT treatment , night throughout course RT treatment , 2 week follow completion RT . Patients localize breast cancer receive standard-of-care RT determine treat physician . The RT regimens include : ( 1 ) 1 week APBI ; ( 2 ) 3-4 week accelerate hypofractionation RT schedule ; ( 3 ) 6-8 week standard RT schedule . No additional concomitant medication supportive care guideline require study . Subjects receive daily melatonin placebo begin night course RT additional 2-week period extend beyond conclusion RT . Subjects give Study Diary record use study medication . Patients follow 60 day removal study treatment death , whichever occur first . Patients remove study treatment unacceptable AEs follow resolution stabilization adverse event .</detailed_description>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Inclusion Criteria 1 . Ambulatory outpatient breast ( include ductal carcinoma situ [ DCIS ] ) cancer . 2 . Patients treat RT curative intent . 3 . Women ≥18 year age . 4 . ECOG performance status &lt; 3 ( Appendix 4 ) . 5 . Hemoglobin ≥ 9 g/dL 6 . Either postmenopausal , surgically sterilize , willing use acceptable method birth control study treatment 3 month afterwards . 7 . Subjects currently take melatonin must discontinue melatonin 5 day enrol study . 8 . Ability understand willingness sign write informed consent document . Exclusion Criteria 1 . Fatigue bring condition cancer ( indicated test require mechanism fatigue suspect ) : uncontrolled hypothyroidism ( TSH &gt; 10 IU ) hypercalcemia ( calcium &gt; 11 mg/dL ) Ca = SerumCa + 0.8 * ( NormalAlbumin PatientAlbumin ) decompensated congestive heart failure chronic obstructive pulmonary disease require oxygen replacement 2 . Patients creatinine clearance &lt; 30 mL/min 3 . Aspartate aminotransferase ( AST ) &gt; 3X upper limit normal ( ULN ) 4 . Alanine aminotransferase ( ALT ) &gt; 3X ULN 5 . Bilirubin &gt; 1X ULN 6 . Use systemic steroid , pharmacological agent methylphenidate cancerrelated fatigue 7 . Current use American ginseng , remelteon , warfarin . 8 . Depression ≥ grade 2 ( CTCAE v4.0 )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>